Life, changing.
More than 600,000 cancer patients worldwide have used our Oncotype DX tests to personalize treatments and improve outcomes.
Our Mission
Genomic Health’s mission is to transform treatment decisions and outcomes in cancer by delivering clinically actionable diagnostics and services.
Oncotype IQ
Our portfolio of tests and services is aimed at delivering genomic intelligence that optimizes treatment decisions and outcomes throughout the cancer patient journey.
Our Pipeline
Developing liquid- and tissue-based genomic tests that address critical treatment questions throughout all stages of cancer.

Making An Impact

Genomic Health is leading in the precision medicine revolution to eliminate the "one-size-fits-all" approach to cancer treatment.
Improving Cancer Outcomes
TAILORx outcomes study in over 10,000 patients in six countries demonstrated 99% of patients with low Oncotype DX Breast Recurrence Score results were free of breast cancer recurrence after five years of hormone therapy alone.
"The Oncotype DX test gives you the peace of mind and the reassurance that the treatment plan that you and your doctor have decided upon is the right one."

Coree H.

Broadening Reimbursement for Patients Worldwide
Genomic Health is dedicated to securing reimbursement to ensure cancer patients around the world have access to our clinically actionable Oncotype DX tests. Outside the U.S., there are over 185 million lives covered and growing. The Oncotype DX prostate cancer test is now covered by Medicare in the U.S. for qualified patients, giving nearly 60,000 prostate cancer patients the opportunity to personalize their cancer treatment.
“I was determined to educate myself about all of my options, and thanks to Oncotype DX, I have not lost any sleep or been worried since I decided to go on active surveillance based on my very low GPS result.”

Dan W.